Nuformix focused on lead asset for pulmonary fibrosis as loss narrows
Nuformix PLC on Tuesday said its preclinical inhalation strategy has ‘significantly progressed’ NXP002 as it reported a narrowed interim loss.
The London-based developer of treatments for fibrosis and oncology said pretax loss narrowed to £660,569 in the financial year ended September 30, from £3.6 million a year prior. The company reported no revenue nor cost of sales for either year.
Administrative expenses widened by 30% to £660,569 from £506,353. Meanwhile, Nuformix posted no impairment of goodwill for financial 2025, compared to £3.6 million in financial 2024.
Looking ahead, the company said the main priority for directors is to focus on the firm’s NXP002 programme and specifically to find a business development partner. NXP002 is Nuformix’s lead asset and novel treatment for progressive pulmonary fibrosis, administered by inhalation.
‘The preclinical inhalation strategy, initiated by the company, has significantly progressed NXP002,’ the firm said, adding that very high doses of the drug appear to be well-tolerated.
Nuformix shares fell 21% to 0.22 pence each on Tuesday afternoon in London.
Copyright 2026 Alliance News Ltd. All Rights Reserved.